Med最新文献

{"title":"Systemic antitumor responses to hypofractionated radiotherapy plus Poly(I:C) in advanced hepatocellular carcinoma: A phase 2 trial.","authors":"Liman Qiu, Qizhen Huang, Xinting Pan, Geng Chen, Wenhui Liu, Kai Wang, Yang Zhou, Rong Xie, Xiuqing Dong, Qiming Wu, Zhenli Li, Yongyi Zeng, Hongbing Ji, Zhixiong Cai, Xiaolong Liu","doi":"10.1016/j.medj.2026.101331","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101331","url":null,"abstract":"<p><strong>Background: </strong>The abscopal effect, regression of unirradiated tumors after localized radiotherapy, is rare. Whether hypofractionated radiotherapy (HFRT) plus the innate immune agonist polyinosinic-polycytidylic acid [Poly(I:C)] amplifies systemic antitumor immunity in advanced hepatocellular carcinoma is unclear.</p><p><strong>Methods: </strong>In this single-arm, phase 2 trial (ChiCTR2100053441), 37 patients received HFRT plus subcutaneous Poly(I:C); 33 were response evaluable. Outcomes were compared with 33 propensity score-matched patients treated with HFRT alone. The primary endpoint was the objective response rate per RECIST v.1.1; secondary endpoints included progression-free survival, overall survival, and safety; and abscopal response was prespecified. Mechanisms were explored by single-cell RNA sequencing and flow cytometry in patients and by CD8 depletion and CD28 blockade in mice.</p><p><strong>Findings: </strong>HFRT plus Poly(I:C) was well tolerated; it was associated with a higher objective response rate (54.5% vs. 21.2%; p = 0.011) and abscopal response rate (45.0% vs. 10.5%; p = 0.042) as well as longer progression-free survival (8.4 vs. 4.6 months; adjusted hazard ratio = 0.542; p = 0.042) and overall survival (not reached vs. 13.6 months; adjusted hazard ratio = 0.386; p = 0.011) vs. HFRT alone. The progression-free survival benefit was also higher in patients concurrently receiving tyrosine kinase inhibitors (p for interaction = 0.013). Peripheral CD8⁺CD28⁺ T cell expansion correlated with abscopal tumor control; in mice, CD8⁺ T cells and CD28 co-stimulation were required for this effect.</p><p><strong>Conclusions: </strong>HFRT plus Poly(I:C) showed promising systemic antitumor activity with manageable safety in advanced hepatocellular carcinoma, with CD8⁺CD28⁺ T cells as an immune correlate of response. These exploratory findings warrant confirmation in randomized trials.</p><p><strong>Funding: </strong>The National Natural Science Foundation of China.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101331"},"PeriodicalIF":13.3,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149228944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpretation of genome sequencing results in children with complex neuromotor phenotypes.","authors":"Jan M Friedman, Anna Lehman, Colleen Guimond, Jill Mwenifumbo, Cyrus Boelman, Patricia Birch, Madeline Couse, Michelle Demos, William T Gibson, Gabriella Horvath, Elena Lopez-Rangel, Kishore Mulpuri, Millan S Patel, Indhu-Shree Rajan-Babu, Kathryn Selby, Zong Yi Ha, Clara D M van Karnebeek","doi":"10.1016/j.medj.2026.101330","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101330","url":null,"abstract":"<p><strong>Background: </strong>Although genetic diseases cause at least 30% of neuromotor disorders, genome sequencing is not routinely used for diagnosis in such patients. We assessed the diagnostic value in children with complex neuromotor phenotypes.</p><p><strong>Methods: </strong>We performed trio genome sequencing in 108 children with complex neuromotor phenotypes in 100 families. Genetic disease was diagnosed by a multidisciplinary clinical research team on the basis of each child's complete medical history, clinical course, family history, physical examination, imaging studies, and all other laboratory test results, as well as the findings on genome sequencing. Genetic variants that were suspected of being disease causing were subjected to orthogonal confirmation in a clinically accredited laboratory, which classified the variants it reported according to the ACMG/AMP guidelines.</p><p><strong>Findings: </strong>We diagnosed genetic diseases that explained the neuromotor phenotype in 53 of the 100 families studied. Almost all of these children had intellectual disability, a seizure disorder, and/or autism spectrum disorder in addition to neuromotor impairment. An important factor contributing to this high diagnostic rate was the use of each patient's complete clinical phenotype, instead of a \"molecular diagnosis\" based only on the ACMG/AMP variant classification.</p><p><strong>Conclusions: </strong>Our findings demonstrate that complex neuromotor phenotypes in children are usually manifestations of a more generalized neurodevelopmental disorder and that the ACMG/AMP classification alone is insufficient to establish or exclude a causal relationship between a genomic variant and a suspected genetic disease.</p><p><strong>Funding: </strong>Canadian Institutes of Health Research, British Columbia Children's Hospital Foundation, and Michael Smith Health Research BC.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101330"},"PeriodicalIF":13.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor DNA methylation subtypes and expression levels of CFISH predict response and overall survival to immunochemotherapy.","authors":"Hannah S Fuchs, Phil Xie, Sabrina A James, Zheyi Cao, Thomas M Carroll, Masato Inoue, Paulina Siejka-Zielińska, Sungyong Kim, Brittany-Amber Jacobs, Emelie Shepherd, Ethan Wang, Joseph A Chadwick, Bob Amess, Duncan Parkes, Simon R Lord, Somnath Mukherjee, Tim Underwood, Ioannis Karydis, Russell Petty, Lucinda Griffiths, Katy J McCann, Sam Wilding, Gareth Griffiths, Cleopatra Pike, Megan Lawrence, Daniel R McGowan, Kevin M Bradley, Skirmantas Kriaucionis, Chun-Xiao Song, Richard P Owen, Benjamin Schuster-Boeckler, Mark R Middleton, Xin Lu","doi":"10.1016/j.medj.2026.101327","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101327","url":null,"abstract":"<p><strong>Background: </strong>Predicting patient response to immunochemotherapy is vital but challenging and poorly studied in the (neo)adjuvant setting. We showed that tumor monocyte content (TMC) predicts overall survival of advanced esophageal cancer (OC) in response to immunochemotherapy. We report clinical outcomes of 35 operable OC patients receiving ICI-based therapy and molecular profiling of the unique phase-2 LUD2015-005 trial treating 73 OC patients (38 advanced/inoperable and 35 operable) in the (neo)adjuvant setting.</p><p><strong>Methods: </strong>LUD2015-005 trial patients were treated with 4-week immune checkpoint inhibitor (ICI)-only before combination with standard of care. Paired and longitudinally collected biopsies of tumor and multiple adjacent normal sites were bi-dissected to extract DNA and RNA. Whole-genome, methylome, single-cell and bulk RNA sequencing data generated from the entire LUD2015-005 cohort were used for cell-deconvolution and data integration analysis.</p><p><strong>Findings: </strong>Neoadjuvant ICI-based combination therapy of operable OC in the LUD2015-005 trial revealed improved overall outcomes. Tumor monocytes contribute to tumor immune microenvironment (TiME) remodeling and associate with tumor reactive CD8⁺ T cells upon ICI+ chemotherapy/chemoradiotherapy. We identified five DNA-methylation subtypes with distinct TiME and a TMC-related five-gene signature CFISH (CXCL8, FCN1, IFI30, SLC11A1, and HLA-DRA) as highly predictive biomarkers of overall survival in OC and beyond.</p><p><strong>Conclusions: </strong>These findings highlight the importance of the myeloid compartment in ICI response and the potential of CFISH and tumor DNA methylation in patient stratification for immunochemotherapy.</p><p><strong>Funding: </strong>This work is mainly funded by Ludwig Institute for Cancer Research, CRUK Grants A21998 and C30423/A2541, and NIHR Oxford Biomedical Research Center. AstraZeneca UK Limited provided durvalumab and tremelimumab for LUD2015-005.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101327"},"PeriodicalIF":13.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endovascular treatment for ischemic stroke due to distal medium vessel occlusions: A nationwide multicenter registry.","authors":"Changwei Guo, Jiaxing Song, Zhenxuan Tian, Chengsong Yue, Gaoming Li, Wenzhe Sun, Boyu Chen, Chong Zheng, Guoyong Zeng, Shengli Chen, Chen Gong, Xiaolei Shi, Lilan Wang, Shihai Yang, Zhongjun Chen, Xiangping Cheng, Changchun Jiang, Shuyu Jiang, Haoxuan Zhu, Jie Yang, Guojian Liu, Miao Chai, Jifei Liu, Hetai Lai, Li Wang, Quanlong Hong, Yong Liu, Weidong Huang, Mengxiu Li, Min Zhang, Weishi Chen, Peiyang Zhou, Jincheng Liu, Yuanjun Shan, Shunfu Jiang, Dahong Yang, Xu Xu, Jinfu Ma, Linyu Li, Jie Tang, Zhaoyun Guo, Shuchun Huang, Jian Wang, Zhibin Ai, Tao Xu, Liping Huang, Zhaoxia Yang, Wei Ma, Nizhen Yu, Xin Zou, Jun Luo, Xiaolin Tan, Youlin Wu, Zhuang Li, Zhouzhou Peng, Kunxin Lin, Xuanyu Chen, Linshan Wu, Linyu Zhang, Kun Luo, Yanjie Huang, Xuan Zhou, Hui Liu, Jun Wen, Hao Tang, Hanming Tu, Zhenchang Zhang, Yaoyu Tian, Jian Shen, Maojun Jiang, Yongtao Guo, Guoping Ma, Duolao Wang, Thanh Nguyen, Raul Nogueira, Mayank Goyal, Jeffrey Saver, Wenjie Zi, Chang Liu","doi":"10.1016/j.medj.2026.101328","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101328","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness and safety of endovascular treatment (EVT) for acute ischemic stroke attributable to distal medium vessel occlusion (DMVO) remain uncertain. This study aimed to compare the effectiveness and safety of EVT plus standard medical treatment (SMT) versus SMT alone in patients with DMVO.</p><p><strong>Methods: </strong>This nationwide multicenter registry included patients with DMVO presenting within 24 h of last known well at 116 sites in China between 2023 and 2025. The primary outcome was freedom from disability (modified Rankin Scale score of 0-1) at 90 days. Safety outcomes included symptomatic intracranial hemorrhage (sICH) within 48 h and 90-day mortality. The primary analysis was conducted using inverse probability of treatment weighting.</p><p><strong>Findings: </strong>Among 2,524 patients, 1,564 received EVT plus SMT, and 960 received SMT alone. EVT plus SMT was associated with a higher rate of freedom from disability at 90 days compared with SMT alone (adjusted risk ratio [aRR], 1.15; 95% confidence interval [CI], 1.02-1.29; adjusted risk difference, 4.36%; 95% CI, 1.73%-6.99%). However, EVT plus SMT was associated with an increased risk of sICH (aRR, 4.03; 95% CI, 2.46-6.59). Mortality at 90 days did not differ significantly between the groups (aRR, 0.97; 95% CI, 0.81-1.16).</p><p><strong>Conclusions: </strong>In patients with DMVO, EVT plus SMT was associated with a modestly higher rate of freedom from disability at 90 days but an increased risk of sICH.</p><p><strong>Funding: </strong>National Natural Science Foundation of China (82425021, 82571498, and 82271349), Natural Science Foundation of Chongqing (CSTB2024NSCQ-MSX0359 and CSTB2024NSCQ-KJFZMSX0063), and Chongqing Technology Innovation and Application Development Project (CSTB2022TIAD-KPX0160).</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101328"},"PeriodicalIF":13.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer plasticity and histological transformation as adaptive resistance mechanisms in precision oncology.","authors":"Nick A Kuburich, Mohamed A Gouda, Breanna R Demestichas, Preetesh Jain, Petra den Hollander, Evgeny Yakirevich, Razelle Kurzrock, Wafik S El-Deiry, Sendurai A Mani, Vivek Subbiah","doi":"10.1016/j.medj.2026.101326","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101326","url":null,"abstract":"<p><p>The advent of precision oncology has brought substantial advancements in cancer therapy, yet it has been accompanied by equally complex resistance mechanisms. Among these mechanisms, histological transformations can compromise the effectiveness of targeted therapies, resulting in a loss of clinical benefit following initial success. Understanding these evolutionary processes is crucial for developing the next generation of cancer treatments that can effectively combat resistance. This review examines histological transformation as a key mechanism of resistance to anticancer therapies, driven by various forms of tumor plasticity, and explores into the underlying processes and mechanisms that drive these changes. We also discuss how precision oncology and an appreciation of cancer plasticity can be leveraged to overcome histological transformation and lead to improved patient outcomes.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101326"},"PeriodicalIF":13.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early detection of gastric cancer using DNA features in red blood cells, with multicenter validation.","authors":"Xingyun Yao, Haobo Sun, Cheng Fang, Qingqu Guo, Jun Wang, Guofeng Chen, Songzhao Zhang, Baozhong Li, Yanwu Jin, Ganshu Xia, Zhiqiang Liu, Fei Meng, Jie Jin, Xiaofei Gao, Yuehua Han","doi":"10.1016/j.medj.2026.101325","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101325","url":null,"abstract":"<p><strong>Background: </strong>Early detection of gastric cancer (GC) is limited by invasive endoscopy and poor sensitivity of blood-based biomarkers. Red blood cells (RBCs), the most abundant cells in the circulation, are anucleate but can retain DNA remnants that have been associated with pathological stress. Here, we report a non-invasive strategy for GC detection based on genome-wide profiling of DNA remnants retained in RBCs (rbcDNA).</p><p><strong>Methods: </strong>We performed shallow whole-genome sequencing of rbcDNA from 1-2 mL of peripheral blood of 865 individuals, including 434 treatment-naive GC patients and 431 non-GC controls with benign gastric conditions. In the discovery cohort, we identified 1,000 reproducible rbcDNA read-depth features distinguishing GC from non-cancer states. A machine learning classifier based on dimensionally reduced GC-associated rbcDNA features was trained in the discovery cohort (n = 435), with the cutoff fixed at 90% specificity, and evaluated in a test cohort (n = 109) and three independent multicenter validation cohorts (n = 321).</p><p><strong>Findings: </strong>The classifier achieved the areas under the receiver operating characteristic curve (AUCs) of 84% in nested cross-validation of the discovery cohort and 95% in the test cohort. Across three hospital-based multicenter validation cohorts, performance remained consistent, with 83%-90% overall sensitivity and 82%-89% sensitivity for stage I GC. Additionally, the classifier distinguished early-stage GC from precancerous lesions and other tumors and detected ∼80% of GC cases negative for tumor markers.</p><p><strong>Conclusions: </strong>These findings demonstrate the potential of rbcDNA as a non-invasive biomarker for early-stage GC detection.</p><p><strong>Funding: </strong>This work was supported by the Key Research and Development Program of Zhejiang Province (2026C02A1176 and 2024C03170).</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101325"},"PeriodicalIF":13.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trunk-mediated spinal cord stimulation: A step toward clinical implementation after spinal cord injury.","authors":"Shovan Bhatia, Peter C Gerszten","doi":"10.1016/j.medj.2026.101304","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101304","url":null,"abstract":"<p><p>In this issue of Med, Agnesi et al., show that residual trunk movements after spinal cord injury can modulate the effects of epidural spinal cord stimulation (SCS) to enable participants to volitionally initiate and control stepping.¹ This trunk-mediated interface offers a practical strategy for bringing epidural SCS one step closer to widespread clinical adoption.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":"7 10","pages":"101304"},"PeriodicalIF":13.3,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Restoring locomotion in motor-complete spinal cord injury via trunk-mediated control using a commercial epidural spinal cord stimulator.","authors":"Filippo Agnesi, Daniele Emedoli, Luigi Albano, Simone Romeni, Filippo Gasperotti, Federico Colombo, Edoardo Pompeo, Mario Sacco, Veronica Fossati, Chiara Ciucci, Laura Toni, Elena Losanno, Andrea Tettamanti, Federica Alemanno, Luigia Brugliera, Paola Castellazzi, Jeffrey D Padul, Lina R Barzaghi, Carlo Mandelli, Cinzia Mura, Heike Caravati, Carla Butera, Ubaldo Del Carro, Antonella Castellano, Andrea Falini, Jacopo Carpaneto, Tommaso Proietti, Solaiman Shokur, Federica Agosta, Massimo Filippi, Sandro Iannaccone, Pietro Mortini, Silvestro Micera","doi":"10.1016/j.medj.2026.101273","DOIUrl":"10.1016/j.medj.2026.101273","url":null,"abstract":"<p><strong>Background: </strong>Spinal cord stimulation is emerging as a novel approach to restore movement in patients affected by spinal cord injury. Recent advances have shown restoration of locomotion in patients with complete motor lesions using sophisticated new systems including a brain machine interface. Despite the great potential, this approach is hindered by the inherent complexity and absence of approvals for clinical use.</p><p><strong>Methods: </strong>Here, we tested a novel strategy to restore locomotion in patients with motor-complete spinal cord injury using voluntary trunk movements to modulate the motor output produced by a commercially available epidural spinal cord stimulator.</p><p><strong>Findings: </strong>Four participants with thoracic AIS A-B injuries gained volitional modulation of stimulation-enabled movement without external interfaces or brain decoding, achieving standing and walking over four months of rehabilitation. The approach transformed passive stimulation into self-initiated movement, enabling functional mobility.</p><p><strong>Conclusions: </strong>This simple and potentially scalable method successfully leverages clinically available spinal cord stimulators to allow locomotion even in patients unable to produce voluntary contractions below the lesion, advancing accessible neuromodulation for motor-complete spinal cord injury.</p><p><strong>Funding: </strong>This work was funded by Università Vita-Salute San Raffaele, Boston Scientific Spa, Fondazione Cariplo, Bertarelli Foundation, #NEXTGENERATIONEU (NGEU), and the Ministry of University and Research (MUR).</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"101273"},"PeriodicalIF":13.3,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Q&A with Mihaela van der Schaar.","authors":"","doi":"10.1016/j.medj.2026.101257","DOIUrl":"10.1016/j.medj.2026.101257","url":null,"abstract":"<p><p>Mihaela van der Schaar is John Humphrey Plummer Professor of Machine Learning, Artificial Intelligence and Medicine, at the University of Cambridge, where she leads the van der Schaar Lab, directs the Cambridge Centre for AI in Medicine, and serves as Chief AI Scientist at the Francis Crick Institute. An IEEE Fellow since 2009 and Fellow of the Royal Society since 2024, she has received major honors including the Johann Anton Merck Award, Cambridge's Oon Prize, and an NSF CAREER Award. She holds 35 US patents, contributed to 45 international standards, earned 3 ISO Awards, and was named the UK's most-cited female AI researcher.</p>","PeriodicalId":29964,"journal":{"name":"Med","volume":"7 10","pages":"101257"},"PeriodicalIF":13.3,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When the standard changes during the trial: Reflections on targeted therapy in FGFR2-rearranged cholangiocarcinoma.","authors":"Alessandro Ottaiano, Guglielmo Nasti, Giovanni Savarese","doi":"10.1016/j.medj.2026.101300","DOIUrl":"https://doi.org/10.1016/j.medj.2026.101300","url":null,"abstract":"","PeriodicalId":29964,"journal":{"name":"Med","volume":"7 10","pages":"101300"},"PeriodicalIF":13.3,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149149000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}